Phenylalanine-free protein substitute in tablet form (xphe minis)    (DrugBank: Phenylalanine)

2 diseases
IDDisease name (Link within this page)Number of trials
75Cushing disease0
240Phenylketonuria1

75. Cushing disease    [ 191 clinical trials,   172 drugs,   (DrugBank: 48 drugs),   61 drug target genes,   121 drug target pathways]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 191 trial found

240. Phenylketonuria    [ 125 clinical trials,   95 drugs,   (DrugBank: 11 drugs),   1 drug target gene,   5 drug target pathways]
Searched query = "Phenylketonuria", "PKU", "Phenylalanine hydroxylase deficiency", "PAH deficiency", "Tetrahydrobiopterin deficiency", "BH4 deficiency", "BH4 reactive hyper pheemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 125 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04375592
(ClinicalTrials.gov)
October 202021/4/2020Acceptability and Tolerance of a Ready-to-use Protein Substitute in Tablet Form for the Dietary Management of PhenylketonuriaXPhe Minis - Acceptability and Tolerance Market ResearchPhenylketonurias;Hyperphenylalaninaemia;Tetrahydrobiopterin DeficiencyDietary Supplement: Phenylalanine-free protein substitute in tablet form (XPhe minis)metaX Institut fuer Diatetik GmbHBirmingham Children's HospitalNot yet recruiting7 Years18 YearsAll10NULL